SANUWAVE Health Surges 42% After SEC Filing Gives Clues To Its Planned NASDAQ Uplist; Special Meeting And Vote By Proxy Set For December 30, 2020

SANUWAVE Health (OTC: SNWV) shares are in rally mode, trading higher by more than 42% intraday on Friday before settling back to a gain of more than 28% for the week. Notably, the volume traded at roughly twice its average pace.

Investors likely responded to two things in particular. First, positive editorial insight pointing toward Lake Street Capital’s coverage of the stock is catching attention. The second interest may have come from an SEC filing made on Friday by SANUWAVE that calls for a Special Meeting on December 30, 2020, to vote on two proposed amendments to its articles. Those agenda items have long been rumored to coincide with the company’s planned listing to a more senior NASDAQ exchange. 

As noted, two proposals are in play. First, an increase in the authorized share count for the company. Second, the company is asking for approval to effect a reverse stock split at an exchange rate of 1:50. The interesting part of each proposal is that the company has noted an increase in A/S, and a proposed stock split, would happen only when its uplist is imminent. Shareholders had already approved a reverse split during a July 23, 2020 meeting, but management did not make the change. This time, there is speculation that they may act on a new authorization to secure their spot on the NASDAQ. Thus, the timing of the filing may have rightfully earned investor’s attention.

Both proposals are being viewed as bullish, and the reverse split, when associated with an uplisting, is a far different action than an uplisting for survival. SANUWAVE, for those not following along, set record-setting Q3 revenues. In fact, they were higher by 895% compared to the same period last year.

Moreover, analyst and company guidance call for a second set of consecutive quarterly records for the period ending December 30, 2020. Full-year guidance is also bullish, expecting revenues to increase by more than 415%, following its near-term Q4 report that anticipates revenues to jump by triple-digit percentages in year over year comparisons. 

Clues to A New Year’s NASDAQ Listing

Investors wanting to understand the reasoning behind the bullish sentiment are encouraged to read the recently published editorial insights about SANUWAVE. Those presentations allude to Lake Street Capital’s bullish thesis expecting to a substantial share price rally from current levels (even after the recent gains) as well as their expectations for revenues to surge to upwards of $25 million in 2021.

Lake Street models propose that SANUWAVE’s position in the $11 billion diabetic foot ulcer treatment market may have cleared all of the high hurdles for entry. Moreover, they note that its acquisition of Celularity’s UltraMIST® ultrasound healing device combined with its own dermaPACE® healing therapy device make the company a best-in-class treatment option for physicians.

The coverage available offers a road-map as to how and why SANUWAVE is positioned to become a market leader in the diabetic chronic wound-care market. That analysis highlights recent acquisitions, market potential, a move into Latin markets, more expected record-setting financial performance, and the company’s most coveted near-term prize- the NASDAQ listing. 

The consensus among investors is that the call for a Special Meeting provides the final clues to what can cap off a transformational year for the company and boost its shares to a more senior market that can immediately attract institutional investment and new analyst coverage. 

Here’s why each proposal, and its respective approvals, are important. 

Effecting A R/S Of its Common Stock 

Ordinarily, investors run from the sound of the words “reverse stock split.” However, in SANUWAVE’s case, management has been transparent that the move will only occur in association with its NASDAQ uplist. Remember, shareholders had already approved an R/S last July, and management didn’t effect the change. Their reluctance to do so showed their commitment to preserving shareholder value and may have revealed a clue as to why this new proposal is back on the table. Evidence suggests that the timing is ripe for its imminent upgrade. And the R/S serves that important premise.

In its filing, SANUWAVE said it submitted the R/S proposal to its stockholders with the primary and obvious intent of increasing the market price of its common stock. Doing so will enhance liquidity and make its shares more attractive to a broader list of investors. Also, having record-setting revenues not only support and justify the exchange, but also position the company to attract a more comprehensive range of investors, including a larger class of institutional investors, professional investors, and other members of the investing public. 

The split would also help clear the internal policies that many brokerage houses and institutional investors have in place that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Remember, institutional money is behind the company’s recent transformational acquisitions, and their interest in participating in future growth is likely. Thus, the proposed change in share structure, which does not change a shareholder’s equity position, can generate meaningful new interest in the stock. 

And, with an after the event O/S count of only 9.3 million, supply and demand for the shares can help bolster the price. Moreover, a NASDAQ uplist is not a “sell the news” event. Thus, January may indeed be an exciting time at SANUWAVE.

Increase In Authorized Shares To Drive Growth

An increase to its authorized share treasury is also bullish in most investors’ views since it provides the company with additional flexibility to issue common stock for various general corporate purposes. It’s not an uncommon practice for companies experiencing significant growth to warrant an increase in A/S and especially not unusual after making a company-changing acquisition. SANUWAVE just did.

Further, an increase in treasury shares is only dilutive after they are issued. So, investors consider it an additional tool in the war chest. Flexibility allows for stock splits, stock dividends, raising capital, and can act as currency for further acquisitions and licensing agreements. Although the company noted that it currently does not have any definitive plans, arrangements, or commitments concerning the issuance of the additional shares of common stock, from an investor’s perspective, having available stock is a significant asset for growth.

Both measures come with Board support, and each should be viewed as positive proposals as the company is clearly on a path to extend its market presence.

Recap Of Record-Setting Financials

Recent performance justifies the two proposals. In Q3, the company posted a record-setting quarter with revenues surging by more than 895% compared to the same quarter last year. Guidance for Q4 calls for roughly $3 million in new revenues, which would contribute to a more than 415% gain in year-over-year revenues. That’s just for starters. 

As part of the due diligence, investors learned that UltraMIST® delivered more than $15 million in sales last year and provided more than $4 million in EBITDA earnings. Also, the UltraMIST® revenues are immediately accretive and are expected to push the company closer to bottom-line profitability or positive cash-flow status relatively quick. The analyst guidance for full-year revenues of $25 million in 2021 supports their bullish premise.

And while those estimates call for serious growth, estimates are likely to increase with its 100 person sales team now representing the company’s FDA-cleared DermaPACE®. When added with UltraMIST®, the two can combine to deliver best-in-class painless treatment alternatives to patients with chronic diabetic wounds. Undoubtedly, the value of both devices together played a role in finalizing the UltraMIST acquisition, and its strength lay in its ability to deliver dual therapeutic value that is quick and virtually painless. They also bring physicians an effective means to treat diabetic wound-care patients along the entire continuum of care. That factor alone could be a defining advantage over competing treatments.

Sum Of The Parts

Clearly, investors responded well to the company’s filing and are likely positioning ahead of what they think will be a surge in growth during 2021. Record-setting revenues, coupled with a low share count and public float, can be a recipe for near term growth. And while the call for a Special Meeting may only serve up clues to what’s in store, investors are apparently taking a bullish stance.

Thus, if the planned uplist happens in January, or even soon before or after, the response could add potentially exponential value. That news would likely coincide with expected and consecutive record revenues, an expansion into global markets, and a considerable reduction in available shares. By any measure, the sum of those parts may equate to a far higher valuation than current prices reflect. 

Now, perhaps it’s more understandable why the stock is in rally mode.


Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. This email and its release to syndicated outlets has been produced and co-independently produced. Hawk Point Media received wire-payment compensation from a third-party in the amount of One-thousand-Five Hundred dollars to research, prepare, and syndicate this content. The producer and author of this content is LONG SANUWAVE Inc. shares. The producer and author of this content will not purchase or sell any shares in SANUWAVE within three days before or after the publication of this article. All content is prepared from publicly available information and is deemed accurate at the time of article preparation. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Blue Hawk Media, LLC
Contact Person: Kenny Feigeles
Country: United States